3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Glioma
8
Glioblastoma
7
Recurrence
3
Osteosarcoma
3
Neuroblastoma
3
Medulloblastoma
3
Ependymoma
3
Central Nervous System Neoplasms
3
Wilms Tumor
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pheochromocytoma
2
Paraganglioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Cholangiocarcinoma
2
Brain Neoplasms
2
Xanthogranuloma, Juvenile
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Neuroendocrine Tumors
1
Meningioma
1
Histiocytic Sarcoma
1
Gliosarcoma
1
Familial ependymoma
1
Esthesioneuroblastoma, Olfactory
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
2
sargramostim
1
poly ICLC
1
pembrolizumab
1
olaparib
1
lutetium Lu 177 dotatate
1
lorvotuzumab mertansine
1
ixabepilone
1
fludarabine
1
cixutumumab
1
aldesleukin
1
Zoledronic Acid
1
Trabectedin
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Interleukin-2
1
Immunotherapy, Adoptive
1
Immunotherapy
1
Drug Therapy
1
Decitabine
1
CLR1404
1
Biological Therapy
1
Ado-Trastuzumab Emtansine
1
Adjuvants, Pharmaceutic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Synovial
×
olaparib
×
CNS
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled